VJHemOnc is committed to improving our service to you

EHA 2019 | Novel agents in CLL: acalabrutinib and zanubrutinib

VJHemOnc is committed to improving our service to you

Barbara Eichhorst

Barbara Eichhorst, MD, from the University Hospital of Cologne, Cologne, Germany, discusses the data so far for acalabrutinib and zanubrutinib, novel BTK inhibitors for chronic lympocytic leukemia (CLL). This interview took place at the 24th Congress of the European Hematology Association (EHA) 2019, held in Amsterdam, Netherlands.

Share this video  

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter